Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients
In this study, the effectiveness of lipid-lowering therapy on mortality and cardiovascular outcomes is explored.Summary: Mortality is inversely associated with the cholesterol level. The degree of inflammation and wasting is a stronger predictor of mortality than are cholesterol levels. Treatment with statins reduces the risk of death and cardiovascular outcomes among patients not yet requiring renal replacement therapy, but is not effective once dialysis is initiated, most likely because other processes, such as inflammation, not affected by lipid-lowering therapy, dominate in the causal pathway leading to adverse outcomes. Fenofibrate is also useful in reducing cardiovascular outcomes and the progression of renal disease among patients with type 2 diabetes not yet requiring dialysis. While the lipid-lowering therapy is effective in patients with the nephrotic syndrome, no long-term outcome studies regarding hard outcomes are available.Key Points: The great increase in cardiovascular outcomes in patients with kidney disease is likely due to a consequence of properties that are unresponsive to the lipid-lowering therapy, most likely inflammation. The lipid-lowering therapy is useful in patients who are not yet in need of dialysis but does not reduce mortality in dialysis patients.Blood Purif 2017;43:196-199
Authors: Fan D, Yang S, Han Y, Zhang R, Yang L Abstract MicroRNAs (miRNAs) are widely known as critical regulators in isoflurane-induced neurotoxicity during the development of brain. Moreover, isoflurane could aggravate cognitive impairment in diabetic rats. The present study was designed to investigate the role and mechanism of miR-140-5p on isoflurane-induced neurotoxicity in diabetic rats. Firstly, a diabetic rat model was established by injection of streptozotocin (STZ) and identified by Morris water maze test. The result indicated that isoflurane treatment exacerbated STZ-induced cognitive impairment, as demo...
Publication date: Available online 19 February 2020Source: Mechanisms of Ageing and DevelopmentAuthor(s): Cui Chen, Min Zhou, Yuchen Ge, Xiaobo WangAbstractAging is a biological phenomenon in which the structure and function of organisms declining with the increasing of age. It has become a major risk factor of human diseases, including diabetes, cancers, cardiovascular diseases and neurodegenerative diseases. Silencing information regulator 2 related enzyme 1(sirtuin1, SIRT1) is an NAD+-dependent deacetylase, which has been reported to be involved in the regulation of cellular senescence and aging. The expression of SIRT1...
Publication date: March 2020Source: The Lancet Diabetes &Endocrinology, Volume 8, Issue 3Author(s): Robert Stirrups
Publication date: March 2020Source: The Lancet Diabetes &Endocrinology, Volume 8, Issue 3Author(s):
Publication date: March 2020Source: The Lancet Diabetes &Endocrinology, Volume 8, Issue 3Author(s): Thomas S J Crabtree, Pratik Choudhary, Peter Hammond, Alistair Lumb, Alasdair McLay, Emma G Wilmot
Publication date: March 2020Source: The Lancet Diabetes &Endocrinology, Volume 8, Issue 3Author(s): Emma G Wilmot, Thomas Danne
ConclusionAn indication for AHI occurs relatively infrequently among hospitalized patients, but when present, AHI occurs in approximately 1 in 3 discharges. AHI appears to be related largely to the degree of hyperglycemia, and diabetes service involvement. Further studies are needed to understand the implications of AHI at hospital discharge on short and long-term outcomes in this population.
ConclusionsConsidering major health and economic problems posed by unrestrained diabetes epidemic in India, research in this area remains highly inadequate.
ConclusionThere was an increase in the prevalence of neuroischemic DFU. The Enterobacteriaceae family replaced SA as the most prevalent pathogen in DFI, with an increase in the isolation of gram-negative microorganisms and mixed polymicrobial cultures. Chronic neuroischemic infected ulcers usually present distinct bacterial isolates; knowledge about the most common agents is warranted in order to better select empiric antibiotic therapy.
This study used 2013-2016 individual-level claims data of Iranian Health Insurance Organization in East Azerbaijan province. All ambulatory care utilizers were included in the study. We determined characteristics and utilization pattern of high-cost patients as well as their predictors. A total of 1 128 149 patients were included. The top 10% of patients accounted for 62.56% of the total expenditure. This skewed expenditure pattern remained relatively stable over the study period. Female sex, older age, cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes increase the odds of being high cost.